Pacira Reports Unaudited Preliminary Sales Results for the Fourth Quarter and Full-Year Ended December 31, 2023
January 04, 2024 at 05:00 pm EST
Share
Pacira reported unaudited preliminary sales results for the fourth quarter and full-year ended December 31, 2023. The company reported fourth quarter EXPAREL net product sales of $143.9 million in 2023, compared with $138.0 million in 2022. Fourth quarter net product sales were comprised of average daily volume growth of 4 percent. Pacira reports average daily growth rates for EXPAREL to account for differences in the number of selling days per reporting period. There were 61 selling days in each of the fourth quarters of 2023 and 2022. Fourth quarter ZILRETTA net product sales of $28.7 million in 2023, compared with $28.0 million in 2022. Fourth quarter iovera° net product sales of $6.0 million in 2023, compared with $4.6 million in 2022. Other revenue, including sales of bupivacaine liposome injectable suspension and royalties, was $2.6 million in the fourth quarter of 2023, compared with $1.4 million in the fourth quarter of 2022.
For the year, the company reported total revenue of $675.0 million compared with $666.8 million for the year ended December 31, 2022.
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
PACIRA BIOSCIENCES, INC. 
